Rex Bionics PLC - Results of General Meeting
Rex Bionics Plc
("Rex Bionics" or the "Company")
Results of General Meeting and Update on Review of Structural Options
This will enable the Company to proceed to completion of the Business Transfer on the basis set out in the Circular. The Company will make a further announcement when the Business Transfer has been completed, expected to be on or about
Capitalised terms in this announcement have the meanings given to them in the Circular, except where the context requires otherwise.
Further to the Company's announcement on
As previously announced, Stifel, the Company's nominated adviser will resign on
Following the Cancellation, the Company will continue as an unquoted entity and, through its nominated Director, provide support and input to Rex Pty, the company responsible for commercialisation of the REX technology, in which Rex Bionics will, on completion of the proposed refinancing, hold a 36% stake. The Company will provide regular updates to its shareholders to designated mailing addresses, and on its website. The Company does not at this time propose to put in place any formal arrangements for the off-market dealings in the Company's shares following the Cancellation.
This announcement contains inside information. The person responsible for arranging for the
release of this announcement on behalf of the Company is
A copy of this announcement has been posted on the Company's website at www.rexbionics.com.
For further information please contact:
Rex Bionics Plc
+44 (0) 7483 167851
+44 (0) 20 7710 7600
+44 (0) 203 709 5700
About Rex Bionics Plc
Rex Bionics is the pioneer of the "REX" that provides robotic standing, walking and exercise support for wheelchair users; and was founded by two British engineers with first-hand experience of the needs of wheelchair users. REX is used by people who have suffered a spinal cord injury, stroke or other traumatic brain injury; and people with multiple sclerosis, muscular dystrophy and cerebral palsy.
We are working with physiotherapists to develop the concept and practice of Robot-Assisted Physiotherapy (RAP); and also offer REX P, for use in the home, enabling customers to walk and stand with their hands free - providing more work and recreation options.
Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep and maintenance of joint range, and a reduction in spasm, pain, common abdominal problems and prescription drug use.
Our commitment to engineering excellence is complemented by a commitment to clinical science and the RAPPER II clinical trial results show high levels of practicality, safety and user enthusiasm.
Our vision is that every day, around the world, thousands of people get relief with REX, from the harm - the pain, discomfort and inconvenience - of neurological accidents and illnesses; and that many will be cured.
REX is not registered for At-Home use in
Enquiries to ([email protected])
This information is provided by RNS
Quick facts: Rex Bionics PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE